Exploring oral candidiasis among cancer patients undergoing chemotherapy in eastern Iran Authors: Abdol Sattar Pagheh, Fatemeh Kardan, Aynaz Ghojoghi, Ahmad Reza Sebzari, Maryam Erfaninejad, Parvin Askari, Seyed Reza Aghili, Eisa Nazar, Masood Ziaee Published: 2024 ABSTRACT AbstractBackground and Objectives:Understanding the epidemiology of Candida species among cancer patients is crucial for preventing invasive infections. This study aimed to identify Candida species and assess risk factors among cancer patients receiving chemotherapy in Birjand, eastern Iran.Materials and Methods:The samples were obtained from the oral cavity of 140 patients and the initial identification of Candida species was carried out through fungal cultures. Subsequently, Candida isolates were molecularly identified using the PCR-RFLP method with the restriction enzyme Msp1. Furthermore, the demographic characteristics, risk factors, and clinical history of the patients were extracted and scrutinized using a multiple logistic regression model.Results:Among the 140 patients examined, 55 individuals (39.3%) tested positive for oral candidiasis (OC). Notably, Hemorrhagic cancer emerged as the most common type of cancer associated with OC (46.7%). The predominant species isolated was the Candida albicans complex (64.8%), followed by the Candida glabrata complex (26.8%). A noteworthy finding was the significant association between the occurrence of OC and the number of chemotherapy sessions (P<0.05). Conversely, no significant correlations were detected between OC and variables such as sex, age, type of cancer, occupation, residence, underlying disease, and drug use (P>0.05).Conclusion:The prevalence of Candida spp. and its correlation with the number of chemotherapy sessions underscored the importance of preventive measures. These findings provided valuable insights for designing targeted interventions to mitigate the burden of oral candidiasis in this vulnerable population.Keywords: Candidiasis, Neoplasms, Chemotherapy adjuvant, Candida, Risk factors, Epidemiology INTRODUCTION Cancer represents as one of the most pressing global health challenges, leading to a significant number of fatalities each year. Current treatment modalities include surgery, radiation therapy, and chemotherapy. While surgery and radiation can be effective for localized tumors, systemic interventions like chemotherapy are essential for metastatic cancers (1, 2). However, chemotherapy often compromises the immune system and adversely affects patients’ quality of life. The immunosuppression caused by chemotherapy, coupled with oral side effects such as mucosal inflammation and dry mouth, increases susceptibility to opportunistic infections (3, 4). Candidiasis includes a wide range of conditions, varying from superficial mucocutaneous disorders to severe invasive diseases. Among the Candida species, Candida albicans is the predominant strain found in the normal oral flora. However, recent trends indicate a significant increase in non-albicans Candida species, particularly among individuals with cancer and immunodeficiency. This rise can be attributed to alterations in the oral microbiota, which are often driven by factors such as immune compromise and the effects of chemotherapy. These changes create an environment conducive to Candida colonization and increase the risk of developing oral mucositis (5). Oral candidiasis is the most prevalent fungal infection in immunocompromised individuals, posing significant risks for cancer patients (6). If left untreated, mucosal candidiasis can escalate to life-threatening systemic infections. Various factors, including prolonged hospital stays, extensive antibiotic use, neoplastic conditions, immunosuppressive therapies, and intubation, contribute to the risk of candidemia (7). Chemotherapy can disrupt the balance of the oral microbiome through its effects on salivary secretion and the increased need for antibiotics, thereby compromising natural defense mechanisms against Candida overgrowth (8). This disruption can lead to the development of oral candidiasis which in patients experiencing severe and prolonged neutropenia may result in systemic candidiasis (9, 10). In oncology, where adherence to treatment and maintaining adequate nutritional intake are crucial, the presence of oral candidiasis can significantly affect systemic outcomes (11, 12). Due to the non-specific clinical manifestations and the lengthy diagnostic processes associated with systemic candidiasis, timely detection of mucosal colonization is critical for mitigating related risks (13). Given the clinical importance of diagnosing oral candidiasis in cancer patients, it is crucial to understand the epidemiology and distribution of Candida species within this vulnerable population. Oral candidiasis can significantly impact treatment outcomes, and increased risk of systemic infections. This study aims to identify the specific Candida species present and assess the associated risk factors among cancer patients receiving chemotherapy in Birjand City, located in eastern Iran. By providing insights into the microbial aspect of oral candidiasis in this specific population, this investigation sought to enhance preventive strategies and optimize patient care in clinical settings. Furthermore, the findings may contribute to a broader understanding of the relationship between chemotherapy, oral health, and opportunistic infections, thereby informing researchers for future research and clinical practices. MATERIALS AND METHODS Study population. This descriptive cross-sectional study was conducted at Iranmehr Hospital in Birjand from April to November 2023, focusing on cancer patients undergoing chemotherapy. The research received approval from Birjand University of Medical Sciences, and the Code of Ethics (IR.BUMS.REC.445.1399) was obtained. The study’s inclusion criteria specified patients who had not received antifungal or azole-prophylaxis before or during radiotherapy. Participants provided written consent and completed a questionnaire encompassing demographic information (such as sex, age, type of cancer, etc.), treatment specifics, and clinical history. Clinical symptoms observed in patients included dry mouth, altered taste perception, oral redness, presence of a white or cream-colored membrane, and a burning sensation. Oral candidiasis was defined to encompass both oral Candida colonization and infection (14). Oral candidiasis involved colony counting on CHROMagar Candida chromogenic medium with a threshold of more than 50 colonies (14, 15). Culture of samples. Sampling was performed using sterile swabs to collect oral specimens, which were subsequently cultured on CHROMagar Candida chromogenic medium (CHROMagar TM, Pioneer, Paris, France). The samples were incubated at 37°C for 48 to 72 hours to facilitate the growth of Candida species. Fungal growth, diversity, and colony counts were assessed every 24 hours during this incubation period. Candida species were identified based on the color of the colonies. Subsequently, the isolates were cultured for 24 hours at 35°C on Sabouraud Dextrose Agar (SDA) supplemented with chloramphenicol from Liofilchem (Italy) to achieve purification. The cultivated species were then transferred to a microtube containing distilled water for long-term storage before molecular examinations. Molecular identification by ITS sequencing. The isolates were cultured on SDA medium for 48 hours at 28°C. The genomic DNA of the colonies was extracted utilizing the phenol-chloroform technique as described previously (16). The DNA extracts were subsequently preserved at −20°C until required for analysis. The specific primer sequences targeting the Internal Transcribed Spacer regions (ITS 1 and ITS 4) were as follows: 5′-TCC GTA GGT GAA CCT TGC GG-3′ (forward) and 5′-TCC TCC GCT TAT TGA TAT GC-3′ (reverse). The PCR amplification was performed under the following conditions: an initial denaturation step at 95°C for 1 minute, followed by 30 cycles of denaturation at 95°C for 60 seconds, annealing at 56°C for 60 seconds, extension at 72°C for 90 seconds, and a final extension at 72°C for 7 minutes. The resulting amplification products were separated by electrophoresis on a 1.2% agarose gel. To identify the species, the PCR product was cut using the restriction enzyme Msp 1, and the species were distinguished by analyzing the pattern of the cuts (17). Data analysis. The data was analyzed by utilizing central and dispersion indicators, frequency tables, and appropriate diagrams. To ensure the normal distribution of quantitative variables, the Kolmogorov-Smirnov test was conducted. For normally distributed variables, the independent t-test was employed to calculate the average between the two groups; otherwise, the nonparametric Mann-Whitney test was utilized. The relationship between qualitative variables was assessed using the chi-square test and Fisher’s exact test. Furthermore, the multiple logistic regression model was applied to identify factors associated with the prevalence of oral candidiasis infection. All analyses were performed using SPSS software version 20, with a significance level set at p <0.05. Ethical approval. The research project was approved by Birjand University of Medical Sciences, and the Code of Ethics was subsequently issued (IR.BUMS.REC.445.1399). In adherence to research ethics principles, written informed consent was obtained from every individual involved in the study. RESULTS Out of the 140 patients undergoing chemotherapy for different types of cancer, 60 (42.85%) were male and 80 (57.15%) were female. The patients’ ages varied from 16 to 83 years, with an average age of 51.34 ± 14.79 years. The study revealed that 55 patients (39.3%) tested positive for oral candidiasis, with a prevalence rate of 38.8% among women and 40% among men. There was no statistically significant difference in the prevalence of oral candidiasis between genders (p=0.88). However, individuals aged over 60 exhibited a significantly higher prevalence of the infection (52%) compared to those under 60 (33%) (p=0.02). Among the participants, 72% resided in urban areas, while 28% lived in rural regions. The chi-square test results revealed no significant association between the patients’ residential status and positive oral candidiasis cases (p=0.61). Furthermore, no significant correlation was observed between the prevalence of oral candidiasis and various factors such as occupation, smoking habits, and substance use (p <0.05) (Table 1). Table 1.Demographic characteristics and prevalence of oral candidiasis among cancer patients undergoing chemotherapy Variables Total Results P-value Negative Positive Age (years)Standard deviation ± mean51/34 ± 14/7952/73 ± 15/2049.18 ± 13.99P= 0.16≥ 6094 (100)63 (67)31 (33)P= 0.02*< 6046 (100)22 (47.8)24 (52.2)GenderFemale80 (100)49 (61.2)31 (38.8)P= 0.88Male60 (100)36 (60)24 (40)LocationCity101 (100)60 (59.4)41 (40.6)P= 0.61Village39 (100)25 (64.1)14 (35.9)OccupationHousewife57 (100)32 (56.1)25 (43.9)Employee or retired27 (100)17 (63)10 (37)P= 0.65Other56 (100)36 (64.3)20 (35.7)SmokingNo132 (100)80 (60.6)52 (39.4)P= 0.99Yes8 (100)5 (62.5)3 (37.5)Drug useNo107 (100)67 (62.6)40 (37.4)P= 0.40Yes33 (100)18 (54.5)15 (45.5)*Significant at the 0.05 level values are reported as number (percentage) or mean ± standard deviation Demographic characteristics and prevalence of oral candidiasis among cancer patients undergoing chemotherapy Significant at the 0.05 level values are reported as number (percentage) or mean ± standard deviation The study findings highlighted that the most common cancer types associated with oral candidiasis were hemorrhagic cancer (46.7%), breast cancer (44.1%), gastrointestinal tract cancer (40%), and other malignancies (31.7%). Nevertheless, the generalized Fisher’s test indicated that there was no significant correlation between the type of cancer and the prevalence of oral candidiasis (p>0.64) (Table 2). The statistical analysis revealed a significant difference in the mean number of chemotherapy sessions and the prevalence of oral candidiasis (p<0.008). Conversely, no significant association was found between the prevalence of oral candidiasis and factors such as prosthetic treatment, surgical history, duration of chemotherapy, hospitalization history, and type of chemotherapy (p< 0.05) (Table 2). Table 2.Comparison of prevalence of oral candidiasis in cancer patients undergoing chemotherapy according to other risk factors Variables Total Results P-value Negative Positive Number of chemotherapy (Standard deviation ± mean)9.56 ± 7.78.41 ± 7.4511.33 ± 7.80.008*Oral prosthesisNo105 (100)63 (60)42 (40)0.76Yes35 (100)22 (62.9)13 (37.1)Underlying disease (At least one)No78 (100)51 (65.4)13 (37.1)0.20Yes62 (100)34 (54.8)28 (45.2)History of surgeryNo31 (100)16 (51.6)15 (48.4)0.25Yes108 (100)68 (63)40 (37)Type of cancerBreast cancer34 (100)19 (55.9)15 (44.1)Gastrointestinal cancer50 (100)30 (60)20 (40)0.64Hematologic cancer15 (100)8 (53.3)7 (46.7)Other41 (100)28 (68.3)13 (31.7)HospitalizationNo111 (100)67 (60.4)44 (39.6)0.86Yes29 (100)18 (62.1)11 (37.9)Type of chemotherapyInjection131 (100)80 (61.1)51 (38.9)0.73Injection-oral9 (100)5 (55.6)4 (44.4)Duration of chemotherapy (Year)2 ≥101 (100)65 (64.4)36 (35.6)0.152 <39 (100)20 (51.3)19 (48.7)*Significant at the 0.05 level values are reported as number (percentage) or mean ± standard deviation Comparison of prevalence of oral candidiasis in cancer patients undergoing chemotherapy according to other risk factors Significant at the 0.05 level values are reported as number (percentage) or mean ± standard deviation In this study, the multiple logistic regression model was employed to determine the factors associated with the prevalence of oral candidiasis (Table 3). The findings of this analysis unveiled that solely the number of chemotherapy cycles exhibited a significant correlation with the prevalence of fungal infection (p<0.05). More precisely, the likelihood of contracting a fungal infection escalated by 7% for every incremental unit in the number of chemotherapy cycles, which was statistically significant (p<0.05) (Table 3). Table 3.The multiple logistic regression model to determine the factors related to the prevalence of oral candidiasis in cancer patients undergoing chemotherapy Variable (base level) OR (95% confidence interval) P-value Number of chemotherapy1.07 (1.01–1.12)0.01*Age(≤60)2.00 (0.85–4.66)0.10>60Duration of chemotherapy(2 ≥)1.40 (0.62–3.15)0.412